GlassScriptPhysician profile
Charles L Heaton
NPI 1326041377
$1,868.91
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2021: $231 · 2022: $267 · 2023: $249 · 2024: $521 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.04 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $334.23 | 2019-2025 | Rocklatan, Clareon Panoptix Pro |
| Carl Zeiss Meditec USA, INC. | $216.91 | 2021 | |
| Rxsight INC | $211.00 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $183.69 | 2019-2023 | |
| Biotissue Holdings INC. | $179.77 | 2023-2025 | |
| Abbvie INC. | $169.09 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $94.00 | 2022 | |
| Lensar, INC. | $73.98 | 2025 | Lensar Laser System |
| Dompe US, INC. | $57.15 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $56.18 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $49.83 | 2019-2025 | Tecnis Simplicity |
| Amgen INC. | $46.93 | 2024-2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $44.73 | 2025 | Omidria |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Ocular Therapeutix, INC. | $32.92 | 2022-2023 | Dextenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $16.91 | 2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.84 | 2019 | |
| Optos, INC. | $13.94 | 2021 | |
| Bausch & Lomb Americas INC. | $12.21 | 2022 | |
| Allergan, INC. | $11.39 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.